JP2016528233A5 - - Google Patents

Download PDF

Info

Publication number
JP2016528233A5
JP2016528233A5 JP2016532164A JP2016532164A JP2016528233A5 JP 2016528233 A5 JP2016528233 A5 JP 2016528233A5 JP 2016532164 A JP2016532164 A JP 2016532164A JP 2016532164 A JP2016532164 A JP 2016532164A JP 2016528233 A5 JP2016528233 A5 JP 2016528233A5
Authority
JP
Japan
Prior art keywords
apo
range
solution
guhcl
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016532164A
Other languages
English (en)
Japanese (ja)
Other versions
JP6530394B2 (ja
JP2016528233A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2014/000790 external-priority patent/WO2015017888A1/en
Publication of JP2016528233A publication Critical patent/JP2016528233A/ja
Publication of JP2016528233A5 publication Critical patent/JP2016528233A5/ja
Application granted granted Critical
Publication of JP6530394B2 publication Critical patent/JP6530394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016532164A 2013-08-08 2014-08-08 混入物除去方法 Active JP6530394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13179755.7 2013-08-08
EP13179755 2013-08-08
PCT/AU2014/000790 WO2015017888A1 (en) 2013-08-08 2014-08-08 Contaminant removal method

Publications (3)

Publication Number Publication Date
JP2016528233A JP2016528233A (ja) 2016-09-15
JP2016528233A5 true JP2016528233A5 (https=) 2017-08-31
JP6530394B2 JP6530394B2 (ja) 2019-06-12

Family

ID=48948309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532164A Active JP6530394B2 (ja) 2013-08-08 2014-08-08 混入物除去方法

Country Status (13)

Country Link
US (3) US10087235B2 (https=)
EP (2) EP3418290A1 (https=)
JP (1) JP6530394B2 (https=)
KR (1) KR102437202B1 (https=)
CN (2) CN109701004B (https=)
AU (1) AU2014305646C1 (https=)
CA (1) CA2920391C (https=)
DK (1) DK3030578T3 (https=)
ES (1) ES2689333T3 (https=)
HK (1) HK1225737B (https=)
NZ (1) NZ631126A (https=)
PL (1) PL3030578T3 (https=)
WO (1) WO2015017888A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ631126A (en) * 2013-08-08 2018-06-29 Csl Ltd Contaminant removal method
US20200376444A1 (en) * 2018-02-19 2020-12-03 Bayer Heal Thcare Llc Modified Filter Membrane and Method
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
WO2020202831A1 (ja) * 2019-03-29 2020-10-08 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
CN111351893A (zh) * 2020-04-28 2020-06-30 黄河三角洲京博化工研究院有限公司 一种利用离子色谱检测盐酸胍样品中胍离子含量的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
WO2003105989A1 (en) 2002-06-14 2003-12-24 Centocor, Inc. Use of a clathrate modifier to promote passage of proteins during nanofiltration
CA2694854C (en) * 2007-08-17 2016-09-27 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
WO2009036460A2 (en) 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
ES2617977T3 (es) * 2010-06-30 2017-06-20 Csl Limited Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma
HUE042314T2 (hu) * 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
HK1220210A1 (zh) 2013-06-05 2017-04-28 Csl Limited 制备载脂蛋白a-i (apo a-i)的方法
NZ631126A (en) * 2013-08-08 2018-06-29 Csl Ltd Contaminant removal method
CN104017076B (zh) * 2014-01-06 2016-07-06 宁波博泰生物技术有限公司 载脂蛋白aⅰ抗血清的制备方法

Similar Documents

Publication Publication Date Title
JP2016528233A5 (https=)
JP2012503489A5 (https=)
Karkar Modalities of hemodialysis: quality improvement
JP2019528740A5 (https=)
CA2643508C (en) Process for obtaining high efficiency human albumin for use in detoxification therapy
JP2013500711A5 (https=)
WO2008036899A3 (en) Methods for removing viral contaminants during protein purification
ES2226587B1 (es) Composicion de trombina estable.
CN102580062A (zh) 人凝血因子Ⅷ与vWF复合物或人凝血因子Ⅷ制剂的干热处理稳定剂
AR043238A1 (es) Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento
CN109701004B (zh) 去除污染物的方法
JP2013194054A5 (https=)
WO2012026596A1 (ja) 熱ヒステリシス活性増加方法、熱ヒステリシス活性の熱失活の低減方法、及び熱ヒステリシス活性増加用組成物
RU2006107533A (ru) Способ получения раствора альфа-1-антитрипсина
KR20140020746A (ko) 카프릴레이트 바이러스 불활성화
WO2022032368A1 (pt) Processo de produção de um antígeno, correspondente aos vírus sars-cov-2 inativado, antígeno, correspondente aos vírus sars-cov-2, inativado, composição antigênica, kits e seus usos.
CN102430116A (zh) 用于人凝血因子ⅷ制剂的干热处理方法及其稳定剂
CN103041380B (zh) 人抗凝血酶制剂干热处理过程中的稳定剂
CN104804078B (zh) 人体血清凝血因子ⅷ中的病毒过滤方法
JP2926722B2 (ja) アルブミン製剤及びその製造方法
KR20050120784A (ko) 알부민 제제의 제조 방법
JP2009519920A5 (https=)
US20240229007A1 (en) Inactivated vaccines & nucleic acid aptamer therapeutics derived therefrom
CN104447987A (zh) 辛酸法血浆免疫球蛋白分离工艺
CN106008706A (zh) 人α1抗胰蛋白酶制品的病毒灭活方法